Next 10 |
BiondVax (NASDAQ: BVXV) , a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently recei...
2023-08-09 18:43:54 ET Stifel has downgraded Morphic ( NASDAQ: MORF ) to hold, stating that it believes open-label data for its anti-inflammatory drug candidate MORF-057 isn't enough to score a near-term M&A deal. Stifel said that while the immunology and inflammation space ...
Lilly Completes Acquisition of DICE Therapeutics PR Newswire INDIANAPOLIS , Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition...
2023-08-07 15:08:21 ET Eli Lilly ( NYSE: LLY ), one of the best performing US pharma stocks so far this year, is scheduled to report Q2 2023 earnings on Tuesday, Aug. 8, before market open. Despite a year-to-date return of ~24% , Lilly is looking to better Q2 results than in...
2023-08-02 15:35:39 ET Dice Therapeutics ( NASDAQ: DICE ) quicky rose 0.5% amid a Nasdaq delisting notice for its $2.4 billion sale to Eli Lilly ( NYSE: LLY ). Dice ( DICE ) stock will be halted immediately after the close on Aug. 8 with the transaction tentait...
BiondVax, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, was featured in a recent analyst report reiterating a Buy recommendation and a $70 target price The report discussed Eli Lilly’s announcement of a definitive...
Lilly Announces Extension of Tender Offer to Acquire DICE PR Newswire INDIANAPOLIS , July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding s...
NEW YORK, NY / ACCESSWIRE / July 9, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: DICE Therapeutics, Inc. (NASDAQ: DICE)...
NEW YORK, NY / ACCESSWIRE / June 25, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: DICE Therapeutics, Inc. (NASDAQ:DICE)'s ...
2023-06-22 13:45:32 ET Shares of clinical-stage biotech Dice Therapeutics (NASDAQ: DICE) jumped by 37.5% during the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence . The big gain came after the company announced ...
News, Short Squeeze, Breakout and More Instantly...
DICE Therapeutics Inc. Company Name:
DICE Stock Symbol:
NASDAQ Market:
DICE Therapeutics Inc. Website:
BiondVax (NASDAQ: BVXV) , a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently recei...
Lilly Completes Acquisition of DICE Therapeutics PR Newswire INDIANAPOLIS , Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition...
BiondVax, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, was featured in a recent analyst report reiterating a Buy recommendation and a $70 target price The report discussed Eli Lilly’s announcement of a definitive...